Effect of LY2216684 on Ambulatory Heart Rate and Blood Pressure in Patients With Major Depressive Disorder Who Are Being Treated With Selective Serotonin Reuptake Inhibitors is a PHASE1 clinical asset sponsored by Eli Lilly and Company in Major Depressive Disorder. SEO and diligence focus: LY2216684, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.